ERBB2 and breast cancer: In this study, we built FTV-based predictive models to predict pCR individually for each HR/HER2 subtype using data from the I-SPY 2 trial and observed different tradeoffs between PPV and sensitivity among HR/HER2 breast cancer subtypes when probability thresholds were selected based on predefined PPV levels.